# MaxCyte to Report First Quarter 2026 Financial Results on May 12, 2026
Canonical URL: https://biopharmsignal.com/news/MXCT/maxcyte-to-report-first-quarter-2026-financial-results-on-may-12-2026
Ticker: MXCT
Company: MaxCyte
Source: MaxCyte
Published: 2026-04-29 20:05 EST
Original Source URL: https://investors.maxcyte.com
## Summary

ROCKVILLE, Md., April 29, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced that it will

## Article Body
ROCKVILLE, Md., April 29, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced that it will
## Recent Company News
- 2026-05-12 20:06 EST — [MaxCyte Reports First Quarter 2026 Financial Results and Reiterates Full Year 2026 Guidance](https://biopharmsignal.com/news/MXCT/maxcyte-reports-first-quarter-2026-financial-results-and-reiterates-full-year-2026-guidance) — Source: MaxCyte
- 2026-04-29 20:05 EST — [MaxCyte to Report First Quarter 2026 Financial Results on May 12, 2026](https://biopharmsignal.com/news/MXCT/maxcyte-to-report-first-quarter-2026-financial-results-on-may-12-2026) — Source: MaxCyte
- 2026-03-31 20:05 EST — [MaxCyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/MXCT/maxcyte-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4) — Source: MaxCyte
- 2026-03-24 20:05 EST — [MaxCyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Full Year 2026 Guidance](https://biopharmsignal.com/news/MXCT/maxcyte-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-full-year-2026-guidance) — Source: MaxCyte
- 2026-03-23 12:05 EST — [MaxCyte Appoints Parmeet Ahuja as Chief Financial Officer](https://biopharmsignal.com/news/MXCT/maxcyte-appoints-parmeet-ahuja-as-chief-financial-officer) — Source: MaxCyte
## Related News
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)
- 2026-07-21 11:30 EST — ABEO — [Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®](https://biopharmsignal.com/news/ABEO/cincinnati-children-s-activated-as-the-seventh-qualified-treatment-center-for-ze-8382d043)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)